Serenta, which develops vaccines targeting chronic infections, has obtained a licence for a vaccine against bacteria that have proven resistant to antibiotics.
Serenta Biotechnology, a biotech spinout of University of Maryland (UM), Baltimore and Northern Arizona University, has gained licensing rights to a new vaccine.
The license was granted by UM Ventures, a joint commercialisation office for UM Baltimore and UM College Park .
Serenta Biotechnology focuses on vaccines against chronic infections. The licence in question is for a vaccine against bacterial infections caused by staphylococcus aureus, which is often resistant to antibiotics.
The vaccine has proven, in mice, to prevent an MRSA…
